DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,194 filers reported holding DANAHER CORPORATION in Q4 2017. The put-call ratio across all filers is 0.78 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $70,626,932 | +10.2% | 284,672 | +6.6% | 0.05% | +6.5% |
Q2 2023 | $64,116,749 | -4.4% | 267,153 | +0.4% | 0.05% | -11.5% |
Q1 2023 | $67,046,877 | -3.6% | 266,016 | +1.5% | 0.05% | -13.3% |
Q4 2022 | $69,570,985 | +13.9% | 262,117 | +10.8% | 0.06% | +1.7% |
Q3 2022 | $61,081,000 | +1.9% | 236,482 | -0.0% | 0.06% | +3.5% |
Q2 2022 | $59,958,000 | -11.4% | 236,504 | +2.5% | 0.06% | -1.7% |
Q1 2022 | $67,706,000 | -9.2% | 230,818 | +1.9% | 0.06% | -7.9% |
Q4 2021 | $74,554,000 | +19.6% | 226,601 | +10.7% | 0.06% | +6.8% |
Q3 2021 | $62,330,000 | +22.2% | 204,736 | +7.7% | 0.06% | +13.5% |
Q2 2021 | $51,008,000 | +43.4% | 190,071 | +20.3% | 0.05% | +26.8% |
Q1 2021 | $35,563,000 | +8.5% | 158,002 | +7.1% | 0.04% | -2.4% |
Q4 2020 | $32,779,000 | +32.6% | 147,562 | +28.5% | 0.04% | +7.7% |
Q3 2020 | $24,728,000 | +42.4% | 114,838 | +16.9% | 0.04% | +30.0% |
Q2 2020 | $17,370,000 | +45.3% | 98,229 | +13.7% | 0.03% | +15.4% |
Q1 2020 | $11,956,000 | -48.9% | 86,382 | -43.3% | 0.03% | -39.5% |
Q4 2019 | $23,376,000 | +8.7% | 152,304 | +2.3% | 0.04% | -2.3% |
Q3 2019 | $21,507,000 | +4.5% | 148,907 | +3.4% | 0.04% | 0.0% |
Q2 2019 | $20,576,000 | +77.3% | 143,969 | +63.8% | 0.04% | +69.2% |
Q1 2019 | $11,606,000 | +31.1% | 87,907 | +2.4% | 0.03% | +8.3% |
Q4 2018 | $8,855,000 | -0.3% | 85,875 | +5.1% | 0.02% | +14.3% |
Q3 2018 | $8,882,000 | +29.7% | 81,741 | +17.8% | 0.02% | +16.7% |
Q2 2018 | $6,849,000 | -1.3% | 69,404 | -2.1% | 0.02% | -5.3% |
Q1 2018 | $6,941,000 | -5.8% | 70,887 | -10.7% | 0.02% | -13.6% |
Q4 2017 | $7,366,000 | +20.0% | 79,361 | +10.9% | 0.02% | 0.0% |
Q3 2017 | $6,140,000 | +31.6% | 71,581 | +29.5% | 0.02% | +22.2% |
Q2 2017 | $4,664,000 | +8.3% | 55,267 | +9.7% | 0.02% | -37.9% |
Q1 2017 | $4,306,000 | -5.3% | 50,375 | -12.8% | 0.03% | -17.1% |
Q4 2016 | $4,548,000 | +25.3% | 57,743 | +23.6% | 0.04% | +2.9% |
Q3 2016 | $3,629,000 | -31.1% | 46,725 | -28.0% | 0.03% | -22.7% |
Q2 2016 | $5,266,000 | +73.5% | 64,903 | +99.6% | 0.04% | +450.0% |
Q1 2016 | $3,035,000 | -37.3% | 32,512 | -38.3% | 0.01% | -38.5% |
Q4 2015 | $4,844,000 | -42.1% | 52,714 | -44.6% | 0.01% | -71.7% |
Q3 2015 | $8,373,000 | +2.5% | 95,158 | +0.0% | 0.05% | +12.2% |
Q2 2015 | $8,171,000 | -2.1% | 95,157 | -4.4% | 0.04% | -4.7% |
Q1 2015 | $8,349,000 | +35.1% | 99,506 | +38.0% | 0.04% | +26.5% |
Q4 2014 | $6,182,000 | +11.9% | 72,124 | -2.6% | 0.03% | +3.0% |
Q3 2014 | $5,524,000 | -1.8% | 74,059 | +3.7% | 0.03% | 0.0% |
Q2 2014 | $5,623,000 | +3.5% | 71,416 | -1.5% | 0.03% | 0.0% |
Q1 2014 | $5,435,000 | -4.8% | 72,472 | -2.0% | 0.03% | -8.3% |
Q4 2013 | $5,711,000 | +12.2% | 73,979 | +1.1% | 0.04% | +5.9% |
Q3 2013 | $5,090,000 | +10.2% | 73,188 | +0.3% | 0.03% | +3.0% |
Q2 2013 | $4,620,000 | – | 72,985 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |